Navigating the Mainstreaming of Psychedelic Drugs in the United States

In recent years, an unprecedented level of interest in the promise of psychedelics has taken hold. In the United States, many types of psychedelics are being investigated for use in treating an array of mental health conditions, including depression, addiction and eating disorders. The U.S. nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) has announced promising phase 3 clinical trial results for MDMA in post-traumatic stress disorder (PTSD) and indicated its intent to submit an application for FDA approval this year. FDA has granted “breakthrough therapy” status for MDMA and psilocybin and recently issued new draft guidance detailing how it will evaluate psychedelic drugs seeking approval. Congress has taken a keen interest in furthering this promising area of research, introducing numerous bipartisan bills and forming the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus.

States, however, are not waiting for federal action. Two states (Oregon and Colorado) have legalized the use of certain psychedelics, and many others are considering similar decriminalization reforms. A recent article in JAMA Psychiatry reports that the number of bills has grown dramatically, from just 5 in 2019 to 36 in 2022.

The potential of the budding psychedelics market is significant, but the challenges can be daunting—from navigating the mix of reforms across the country to understanding the emerging health care issues around usage and payment. In the first of a new CLE-eligible webinar series on the emerging psychedelic drug market, Manatt provides an overview of the numerous legal and regulatory complexities surrounding the increased investment and interest in psychedelics and helps you carve a path to success. Key topics that will be covered include:

  • An overview of the current legal landscape across the country
  • An update on activities relating to FDA review and approval of psychedelics
  • Key insights into how mental health parity and other relevant regulations are likely to impact coverage of psychedelic-assisted therapy
  • The implications of health policy reforms on the market
  • A look ahead at what to expect next—and how you can prepare for success in an emerging market


Anita Famili, Partner, Lead, Cannabis and CBD Practice
Joseph Laska, Partner, Health Care Litigation
Rachel Sher, Partner, Manatt Health

Date and Time

Tuesday, October 3


This program has been approved for 1.0 NY CLE Skills (transitional and non-transitional) and is pending approval for 1.0 CA MCLE General credit. 

If you would like to receive an audio transcript of this webinar due to accessibility issues, please email us at

This program does not constitute legal advice, nor does it establish an attorney-client relationship. Views expressed by presenters are strictly their own and should not be construed to be the views of Manatt or attributed to Manatt.



pursuant to New York DR 2-101(f)

© 2024 Manatt, Phelps & Phillips, LLP.

All rights reserved